Name
OÜ Hagarex
Registry code
10329273
VAT number
EE100359347
Type
OÜ - Limited Liability Company
Status
Registered
Foundation date
24.11.1997 (26)
Financial year
01.01-31.12
Capital
15 338.00 €
Activity
4646 - Wholesale of pharmaceutical goods
-
-
-
-
-
-
Not submitted
No tax arrears
-
-
| Owner | Representative | Beneficial owner | Roles | |
|---|---|---|---|---|
| OÜ Eskerton 10683230 | 100% - 15 338.00 EUR | - | - | |
| Rasmus Kuklane 04.10.1983 (40) | - | Board member | - | |
| Indrek - Eston Kuklane 21.02.1970 (54) | - | - | Direct ownership | |
| Margus Kuklane 06.05.1964 (60) | - | - | Direct ownership | |
| Larssen Legal OÜ 10167445 | - | - | - | Founder |
| Owner | Representative | Beneficial owner | Roles | |
|---|---|---|---|---|
| Osaühing Pharmax Group 14994990 | - | - | - | Founder |
| 2019 22.12.2020 | 2020 05.11.2021 | 2021 08.07.2022 | 2022 11.07.2023 | |
|---|---|---|---|---|
| Total Revenue | 453 690 € | 724 223 € | 817 604 € | 791 232 € |
| Net profit (loss) for the period | 32 131 € | 141 226 € | 138 755 € | 94 770 € |
| Profit Margin | 7% | 20% | 17% | 12% |
| Current Assets | 403 544 € | 578 928 € | 713 858 € | 844 567 € |
| Fixed Assets | 62 117 € | 32 600 € | 69 075 € | 171 323 € |
| Total Assets | 465 661 € | 611 528 € | 782 933 € | 1 015 890 € |
| Current Liabilities | 9 248 € | 13 889 € | 46 539 € | 184 726 € |
| Non Current Liabilities | - | - | - | - |
| Total Liabilities | - | - | - | - |
| Share Capital | - | - | - | - |
| Equity | 456 413 € | 597 639 € | 736 394 € | 831 164 € |
| Employees | 2 | 2 | 2 | 2 |
| Turnover | State taxes | Labor taxes and payments | Employees | |
|---|---|---|---|---|
| 2024 Q1 | 715 472.43 € | 31 712.35 € | 1 475.79 € | 1 |
| 2023 Q4 | 470 494.64 € | 21 831.44 € | 2 459.39 € | 1 |
| 2023 Q3 | 384 565.74 € | 23 462.37 € | 2 262.69 € | 2 |
| 2023 Q2 | 643 743.39 € | 25 565.99 € | 2 214.51 € | 2 |
| 2023 Q1 | 682 159.09 € | 36 236.04 € | 2 262.69 € | 2 |
| 2022 Q4 | 359 711.31 € | 17 329.28 € | 2 262.69 € | 2 |
| 2022 Q3 | 307 607.81 € | 12 450.05 € | 2 262.69 € | 2 |
| 2022 Q2 | 246 638.54 € | 18 623.98 € | 2 145.93 € | 2 |
| 2022 Q1 | 518 298.23 € | 26 875.1 € | 2 285.52 € | 2 |
| 2021 Q4 | 318 947.66 € | 22 660.88 € | 2 718.26 € | 2 |
| 2021 Q3 | 279 404.88 € | 11 659.25 € | 3 457.6 € | 2 |
| 2021 Q2 | 378 623.46 € | 25 009.63 € | 3 472.58 € | 2 |
| 2021 Q1 | 360 857.38 € | 17 975.84 € | 2 941.91 € | 2 |
| 2020 Q4 | 193 039.94 € | 18 604.51 € | 2 798 € | 1 |
| 2020 Q3 | 335 764.81 € | 15 038.42 € | 3 141.45 € | 1 |
| 2020 Q2 | 206 523.24 € | 15 494.65 € | 2 866.17 € | 2 |
| 2020 Q1 | 350 917.78 € | 19 247.88 € | 3 116.51 € | 2 |
